Current state of developing advanced therapies for rare diseases in the European Union

Abstract

Objective: Advanced Therapy Medicinal Products (ATMPs) present significant therapeutic advantages for inherited rare diseases. However, the development of orphan ATMPs is challenging due to their complexity and unpredictable biological activity. This study aims to comprehensively describe the current state of orphan ATMPs in Europe. Methods: Orphan drugs (ODs) granted by European Commission until March 2020 were investigated. The characteristic of diseases and ATMPs were extracted from the public summary reports of ODs from Committee for Orphan Medicinal Products. The methodology for the pivotal studies of ATMPs was extracted. Results: A total of 274 ATMPs were identified, covering 116 rare diseases, with metabolic, optical, and oncologic diseases being the most targeted. A total of 158 ATMPs were indicated for life-threatening diseases, 129 ATMPs targeted diseases currently lacking authorized or satisfactory treatment available. Twenty-eight ATMPs are being investigated in the phase II/IIII or phase III studies. The median patient size of pivotal studies was 127, 15 were open-label studies, 8 were single-arm trials, and 14 reported surrogate outcomes. Conclusion: There are rapid growths in developing ATMPs for life-threatening diseases with high unmet clinical needs. Optimizing the study methodology and exploring innovative design to facilitate the market access is paramount.

Crossing Disease Boundaries: How AI Drives Rare Disease Drug Discovery

“…The development of rare disease drugs still needs to face strict regulatory approvals and complex market environments. Due to the particularity and complexity of rare disease drugs, their development process requires strict regulatory approval to ensure the safety and efficacy of the drugs (Qiu et al, 2020). This includes the design and implementation of clinical trials, as well as the evaluation of drug safety and efficacy.…”

Rare disease patients’ needs: an up-to-date analysis and future directions

“…Qiu et al defined them as a significant therapeutic advantage for inherited rare diseases. Around 50% of the investigated advanced therapies were indicated for rare diseases which put the discussion that orphan advanced therapies are able to provide new opportunities for patients with life-threatening rare diseases (Qiu et al 2020). However, further remarks related to advanced therapies for rare diseases compared with other traditional orphan medicines need to be addressed -their complex process of development, unpredictable biological activity, the durability of benefits, the potential risks and very high price (Fig.…”